Formerly known as CytRx Corporation, LadRx Corporationis engaged in the development and commercialization of pharmaceutical-related products and services primarily involving human therapeutics focused on high-value critical-care therapies. The Phase III clinical trials for the treatment of acute sickle cell crisis. LadRx is also developing FLOCOR for acute respiratory disorders and has plans to expand its development for other vascular disorders such as shock and stroke over time. LadRx is also currently engaged in research in the areas of infectious disease, gene and drug delivery, vaccines, and animal feed additives
